Amifostine is indicated for reducing the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. It is also used to reduce the incidence of moderate to severe xerostomia (dry mouth) in patients undergoing postoperative radiation treatment for head and neck cancer. Additionally, ongoing research is exploring its potential benefits in other oncological treatments.
